Clomiphene – Kodiac biolabs

Plain-language summaryIntrigue 60 / 100

Clomiphene (Clomid) is the original ovulation-induction drug, FDA-approved in 1967 and still in widespread fertility use. It is a SERM sold as a roughly 60/40 racemic mixture of two isomers with opposite estrogen-receptor effects. The dominant active form, enclomiphene, blocks estrogen receptors in the hypothalamus, lifting the brake on the pituitary and triggering FSH and LH surges that stimulate ovulation. The minor agonist isomer, zuclomiphene, has a long half-life and produces lingering estrogenic effects (hot flashes, mood effects) that some users find unpleasant. Off-label, it is used in men to raise endogenous testosterone while preserving fertility, and as post-cycle therapy by steroid users. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

42/100

Proven 1967 SERM with strong clinical record but low novelty; enclomiphene supersedes it for serious research

Look, clomiphene works. It’s been inducing ovulation since 1967, it’s the standard-of-care reference for anovulatory infertility, and the HPG axis biology it exploits is genuinely elegant. Hypothalamic ER antagonism via the enclomiphene fraction releases negative feedback on GnRH, FSH and LH rise, follicles develop. That mechanism is real, well-validated, and medically important. But “medically important” and “interesting research target” aren’t the same thing, and that distinction is exactly what this score reflects.

The fundamental problem with clomiphene as a research compound in 2026 is that its own component has lapped it. Enclomiphene citrate, the (E)-isomer responsible for essentially all the HPG-stimulating work, is the cleaner and more researchable version of this molecule. The zuclomiphene fraction, roughly 38 percent of the racemate, is a long-half-life ER agonist with a t1/2 around 30 days. That lingering agonist activity produces cervical mucus changes, antiestrogen rebound at later cycles, and real interference in the male hypogonadism protocols where clomiphene gets most of its current off-label traction. If you’re studying HPG axis modulation with any precision, you dont want zuclomiphene accumulating in the background. Androxal exists precisely because of this problem.

The male hypogonadism angle is where current investigator interest concentrates. Driving endogenous testosterone via central FSH/LH elevation preserves fertility in a way exogenous androgen replacement doesn’t, and the clinical rationale is sound. But the evidence base here is real and thin at the same time: a handful of RCTs, reasonable effect sizes, not phase 3 territory, and mostly underpowered against direct enclomiphene comparisons. We think the more scientifically productive route for a lab building on this biology is to start with the isolated isomer rather than the racemate.

On the evidence axis, clomiphene scores well because it’s an FDA-approved drug with decades of replicated clinical data on ovulation induction. You can’t argue with that. But high evidence quality on an approved indication doesn’t rescue novelty or differentiation. The mechanism has been worked out for half a century. The bench utility is real but narrow: useful as a reference SERM for HPG axis studies, useful for isomer-comparison experiments, but not a compound that lets you answer questions you couldnt otherwise answer with enclomiphene directly. It’s a historical reference probe at this point, not a frontier tool.

Honestly, clomiphene’s story is mostly complete. Its own cleaner isomeric form supersedes it for any focused research program. The racemate is well-sourced and well-characterized, which makes it appropriate as a comparator or reference standard. It’s not a priority acquisition target for a lab oriented toward the frontier.

Novelty: 22
Mechanism promise: 28
In-category differentiation: 25
Evidence quality: 78
Translational signal: 72
Research bench value: 40

Rationale Clomiphene earns high evidence and translational scores as an FDA-approved drug with multi-decade clinical replication on ovulation induction, but the racemate is substantially superseded by its own (E)-isomer for research purposes, and novelty and differentiation scores appropriately reflect a fully characterized 60-year-old compound whose more interesting half already has a dedicated clinical development program.

Triphenylethylene SERM (mixed isomers)

A racemic mixture of enclomiphene (anti-estrogen) and zuclomiphene (estrogen agonist); the prototype ovulation-inducing agent.

Abstract

Clomiphene (2-[4-[(E/Z)-2-chloro-1,2-diphenylvinyl]phenoxy]-N,N-diethylethanamine; CAS 911-45-5; molecular formula C26H28ClNO; molecular weight 405.96) is a triphenylethylene SERM developed at Merrell and approved by the FDA in 1967 under the trade name Clomid. The compound is sold as a racemic mixture of approximately 38 percent zuclomiphene ((Z)-isomer, an ER agonist) and 62 percent enclomiphene ((E)-isomer, an ER antagonist). The therapeutic effect in ovulation induction is driven primarily by enclomiphene-mediated antagonism of hypothalamic ER, releasing the negative feedback on GnRH and consequently increasing pituitary FSH and LH; the resulting follicular development drives ovulation. The zuclomiphene component is approximately 5-fold longer half-life than enclomiphene (zuclomiphene t1/2 approximately 30 days, enclomiphene t1/2 approximately 30 hours), causing the agonist component to dominate at later cycles and produce some unwanted estrogen-like effects (cervical mucus changes, antiestrogen rebound). Approved for ovulation induction in anovulatory women. Off-label use in male hypogonadism (induces endogenous testosterone via the same FSH/LH route) is common. Used as the canonical triphenylethylene SERM with HPG-stimulating activity.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-274Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.